FDA Regulation of Cannabidiol (CBD) Consumer Products: Overview and Considerations for Congress [January 21, 2020] [open pdf - 1MB]
From the Document: "Cannabidiol (CBD), a compound in the 'Cannabis sativa' plant, has been promoted as a treatment for a range of conditions, including epileptic seizures, post-traumatic stress disorder, anxiety, inflammation, and sleeplessness. However, limited scientific evidence is available to substantiate or disprove the efficacy of CBD in treating these conditions. In the United States, CBD is marketed in food and beverages, dietary supplements, cosmetics, and tobacco products such as electronic nicotine delivery systems (ENDS)--products that are primarily regulated by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FFDCA, 21 U.S.C. §§301 et seq.). CBD is also the active ingredient in Epidiolex, an FDA-approved pharmaceutical drug."
CRS Report for Congress, R46189
Congressional Research Service: https://crsreports.congress.gov/